Autolus Therapeutics plc (NASDAQ:AUTL) Expected to Post Q1 2023 Earnings of ($0.37) Per Share

Autolus Therapeutics plc (NASDAQ:AUTL – Get Rating) – Jefferies Financial Group issued their Q1 2023 EPS estimates for Autolus Therapeutics in a report released on Wednesday, March 8th. Jefferies Financial Group analyst K. Shi forecasts that the company will earn ($0.37) per share for the quarter. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($1.18) per share. Jefferies Financial Group also issued estimates for Autolus Therapeutics’ Q2 2023 earnings at ($0.42) EPS, Q3 2023 earnings at ($0.44) EPS, Q4 2023 earnings at ($0.43) EPS, FY2023 earnings at ($1.66) EPS, FY2024 earnings at ($1.65) EPS, FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.27) EPS and FY2027 earnings at ($0.63) EPS.

Several other research firms have also commented on AUTL. Needham & Company LLC restated a “buy” rating and issued a $7.00 price target on shares of Autolus Therapeutics in a report on Tuesday, March 7th. Mizuho reduced their price objective on shares of Autolus Therapeutics from $18.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, March 8th.

Autolus Therapeutics Stock Down 4.5 %

Shares of NASDAQ:AUTL opened at $1.90 on Monday. The firm has a fifty day simple moving average of $1.96 and a two-hundred day simple moving average of $2.38. The stock has a market capitalization of $328.81 million, a P/E ratio of -1.21 and a beta of 1.59. Autolus Therapeutics has a 52 week low of $1.60 and a 52 week high of $4.73.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Sei Investments Co. purchased a new stake in Autolus Therapeutics in the 4th quarter valued at about $29,000. CI Private Wealth LLC acquired a new position in shares of Autolus Therapeutics in the 4th quarter valued at approximately $28,000. Armistice Capital LLC acquired a new stake in shares of Autolus Therapeutics during the 4th quarter valued at approximately $19,426,000. Nantahala Capital Management LLC raised its position in shares of Autolus Therapeutics by 47.2% during the 4th quarter. Nantahala Capital Management LLC now owns 7,782,018 shares of the company’s stock valued at $14,786,000 after acquiring an additional 2,495,930 shares in the last quarter. Finally, TFG Asset Management GP Ltd grew its stake in Autolus Therapeutics by 173.1% during the 4th quarter. TFG Asset Management GP Ltd now owns 8,300,000 shares of the company’s stock worth $15,770,000 after buying an additional 5,260,619 shares during the last quarter. 70.06% of the stock is currently owned by hedge funds and other institutional investors.

About Autolus Therapeutics

(Get Rating)

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells.